---
schema_version: "secwatch.filing_event.v1"
accession: "0001740797-26-000011"
form_type: "8-K"
ticker: "AVAI"
cik: "0001740797"
company_name: "AVAI BIO, INC."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:08:55.103856+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AVAI Bio and Ainnova Tech mutually terminate JV agreement as of May 7, 2026

## Summary
- No penalties incurred; all obligations and liabilities under the License Agreement (Nov 8, 2024) released.
- Joint venture Ai-Nova Acquisition Corp. (AAC) to be formally dissolved per Nevada law.
- Each party retains its own intellectual property; all cross-licenses revoked.
- Both parties execute mutual releases of all claims arising from the JV.
- Company states the termination reflects independent business strategies going forward.

## SEC filing metadata
- accession: 0001740797-26-000011
- form_type: 8-K
- ticker: AVAI
- cik: 0001740797
- company_name: AVAI BIO, INC.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740797/000174079726000011/0001740797-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740797/000174079726000011/avai_8kmay82026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001740797-26-000011
- JSON: https://secwatch.observer/filing/0001740797-26-000011.json
- Plain text: https://secwatch.observer/filing/0001740797-26-000011.txt

## Source-grounded claims
- claim_id: 087d58ac03cb3b79f0c971774ad040462bd770b3
  claim: AVAI BIO, INC. terminated Joint Venture and License Agreement with Ainnova Tech Inc. valued at No termination penalties or further financial obligations will be incurred by either party. (effective 2026-05-07).
  evidence_excerpt: On May 7, 2026, Avai Bio, Inc., formerly known as Avant Technologies Inc. (the “Company” or “AVAI”), and Ainnova Tech Inc. (“Ainnova” or “AINN”) entered into a Mutual Termination Agreement (the “Termination Agreement”) to terminate, by mutual consent, the Joint Venture and License Agreement dated November 8, 2024 (effective as of November 11, 2024) (the “License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740797/000174079726000011/0001740797-26-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.